The Centers for Medicare and Medicaid Services (CMS) has issued important new guidance to states, addressing restrictions that state Medicaid programs and Medicaid Managed Care Organizations (MCOs) have instituted to limit access to newer treatments for the hepatitis C virus (HCV). These restrictions were outlined in a June 2015 journal article, “Restrictions for Medicaid Reimbursement of Sofosbuvir […]

Go to Original Post